Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 251,102 | 169,946 | 137,198 | 116,047 | 95,565 |
| Marketable Securities | 155,427 | 135,767 | 104,805 | 101,582 | 92,198 |
| Receivables | 211,328 | 233,949 | 213,023 | 228,710 | 228,540 |
| Inventories | 40,912 | 38,052 | 38,148 | 37,218 | 35,560 |
| TOTAL | $691,411 | $613,870 | $549,211 | $527,553 | $482,257 |
| Non-Current Assets | |||||
| PPE Net | 12,013 | 12,249 | 12,903 | 13,850 | 14,329 |
| Intangibles | 815,435 | 870,908 | 928,392 | 986,690 | 1,053,735 |
| Other Non-Current Assets | 137,975 | 110,301 | 102,125 | 103,295 | 113,270 |
| TOTAL | $965,423 | $993,458 | $1,043,420 | $1,103,835 | $1,181,334 |
| Total Assets | $1,656,834 | $1,607,328 | $1,592,631 | $1,631,388 | $1,663,591 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 29,000 | 64,583 | 64,583 | 64,583 | 64,583 |
| Accounts payable and accrued liabilities | 10,659 | 7,647 | 10,890 | 17,853 | 3,934 |
| Accrued Expenses | 380,730 | 361,076 | 370,194 | 378,405 | 410,766 |
| Other current liabilities | 17,565 | 17,584 | 17,604 | 24,565 | 28,956 |
| TOTAL | $440,028 | $452,929 | $464,609 | $486,710 | $509,510 |
| Non-Current Liabilities | |||||
| Long Term Debt | 542,112 | 505,583 | 520,648 | 535,698 | 550,733 |
| Deferred Revenues | 667 | 667 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 363,908 | 364,730 | 365,168 | 364,546 | 364,506 |
| TOTAL | $915,131 | $879,591 | $895,816 | $910,244 | $925,239 |
| Total Liabilities | $1,355,159 | $1,332,520 | $1,360,425 | $1,396,954 | $1,434,749 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 31,753 | 31,611 | 31,502 | 32,142 | 31,486 |
| Common Shares | 41 | 41 | 40 | 40 | 40 |
| Retained earnings | -101,129 | -118,092 | -149,599 | -161,582 | -163,999 |
| Other shareholders' equity | 809 | 782 | 827 | 736 | 550 |
| TOTAL | $301,675 | $274,808 | $232,206 | $234,434 | $228,842 |
| Total Liabilities And Equity | $1,656,834 | $1,607,328 | $1,592,631 | $1,631,388 | $1,663,591 |